

This policy applies to the following:

Standard Control (SF)	Managed Medicaid Template (MMT)	ACSF Chart (ACSFC)	Medical Benefit	✓	Medicare Part B	Reference #
Standard Control – Choice (SCCF)	Marketplace (MF)	SF Chart (SFC)	Medical: Advanced Biosimilars First	✓	Medicare Part B: Advanced Biosimilars First	3792-D
Preferred Drug Plan Design (PDPD)	Aetna Health Exchange (AHE)	VF Chart (VFC)	Medical Benefit: Managed Medicaid			
Advanced Control Specialty (ACSF)	IVL	New to Market (NTM)	Medical Benefit: Add-on			
Advanced Control Specialty – Choice (ACSCF)	Value (VF)					

EXCEPTIONS CRITERIA BONE METASTASES

PREFERRED PRODUCTS: PAMIDRONATE AND ZOLEDRONIC ACID

POLICY

This policy informs prescribers of preferred products and provides an exception process for targeted products through prior authorization.

I. PLAN DESIGN SUMMARY

This program applies to the bone metastases products specified in this policy. Coverage for the targeted product is provided based on clinical circumstances that would exclude the use of the preferred products and may be based on previous use of a product. The coverage review process will ascertain situations where a clinical exception can be made. This program applies to members who are new to treatment with a targeted product for the first time.

Each referral is reviewed based on all utilization management (UM) programs implemented for the client.

Table. Bone Metastases Products

	Product(s)
Preferred*	<ul style="list-style-type: none"> pamidronate zoledronic acid
Targeted	<ul style="list-style-type: none"> Xgeva (denosumab)

*: Medications considered formulary or preferred on your plan may still require a clinical prior authorization review.

II. EXCEPTION CRITERIA

This program applies to members requesting treatment for an indication that is FDA-approved for any of the preferred products.

Coverage for a targeted product is provided when any of the following criteria is met:

- Member has received treatment with the targeted product in the past 365 days.
- Member has a documented inadequate response with either of the preferred products.
- Member has a documented intolerable adverse event or documented contraindication to therapy with both the preferred products (i.e., severe renal impairment [creatinine clearance less than 35 mL/min]).

This policy applies to the following:

	Standard Control (SF)		Managed Medicaid Template (MMT)		ACSF Chart (ACSFC)		Medical Benefit	✓	Medicare Part B
	Standard Control – Choice (SCCF)		Marketplace (MF)		SF Chart (SFC)		Medical: Advanced Biosimilars First	✓	Medicare Part B: Advanced Biosimilars First
	Preferred Drug Plan Design (PDPD)		Aetna Health Exchange (AHE)		VF Chart (VFC)		Medical Benefit: Managed Medicaid		
	Advanced Control Specialty (ACSF)		IVL		New to Market (NTM)		Medical Benefit: Add-on		
	Advanced Control Specialty – Choice (ACSCF)		Value (VF)						

Reference #
3792-D

REFERENCES

1. Pamidronate [package insert]. Morgantown, WV: Mylan Institutional LLC.; July 2023.
2. Xgeva [package insert]. Thousand Oaks, CA: Amgen Inc.; June 2020.
3. Zoledronic acid [package insert]. Memphis, TN: Northstar Rx LLC; April 2019.